Abstract
The steep dose-response curve for most chemotherapeutic drugs and the need to overcome tumor resistance has resulted in renewed interest in the use of high-dose chemotherapy. Bone marrow rescue has allowed the dose-limiting barrier of hematopoietic suspension to be overcome. However, despite such salvage methods and the use of blood products and effective antibiotics, myelosuppression remains a major obstacle to treatment. The use of recombinant colony-stimulating factors in combination with bone marrow following high-dose chemotherapy may well shorten the period of neutropenia and reduce the frequency of neutropenia-related complications, thus making high-dose treatment more acceptable.
| Original language | English |
|---|---|
| Pages (from-to) | 377-385 |
| Number of pages | 9 |
| Journal | Israel Journal of Medical Sciences |
| Volume | 28 |
| Issue number | 6 |
| State | Published - 1 Jan 1992 |
| Externally published | Yes |
Keywords
- Autologous bone marrow transplantation
- Bone marrow rescue
- Colony-stimulating factors
- High-dose chemotherapy